EA199600103A1 - Способ лечения болезни сердца, фильтрованный инъекционный препарат аденовирусного вектора, способ получения вирусного штамма, рекомбинантный вектор, клетка-хозяин, способ получения рекомбинантного аденовирусного вектора, способ лечения болезни периферических сосудов и способ ограничения доставки трансгена и его экспрессии в одном органе или структуре - Google Patents

Способ лечения болезни сердца, фильтрованный инъекционный препарат аденовирусного вектора, способ получения вирусного штамма, рекомбинантный вектор, клетка-хозяин, способ получения рекомбинантного аденовирусного вектора, способ лечения болезни периферических сосудов и способ ограничения доставки трансгена и его экспрессии в одном органе или структуре

Info

Publication number
EA199600103A1
EA199600103A1 EA199600103A EA199600103A EA199600103A1 EA 199600103 A1 EA199600103 A1 EA 199600103A1 EA 199600103 A EA199600103 A EA 199600103A EA 199600103 A EA199600103 A EA 199600103A EA 199600103 A1 EA199600103 A1 EA 199600103A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gene transfer
mediated angiogenesis
femoral
angiogenesis therapy
diseases
Prior art date
Application number
EA199600103A
Other languages
English (en)
Other versions
EA001616B1 (ru
Inventor
Фрэнк Дж. Джордано
Вольфганг Х. Диллмэн
Х. Кэрк Хэммонд
Original Assignee
Зе Риджентс Оф Зи Юниверсити Оф Кэлифонье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27015408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199600103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/485,472 external-priority patent/US5792453A/en
Application filed by Зе Риджентс Оф Зи Юниверсити Оф Кэлифонье filed Critical Зе Риджентс Оф Зи Юниверсити Оф Кэлифонье
Publication of EA199600103A1 publication Critical patent/EA199600103A1/ru
Publication of EA001616B1 publication Critical patent/EA001616B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Аденовирусный вектор с инсерцией трансгена и дефектом репликации эффективно применяют в генной терапии in vivo заболеваний периферических сосудов и сердечных заболеваний, в том числе ишемии миокарда, посредством однократной инъекции в бедренную или коронарную артерию, которую проводят глубоко в полость одной или обеих бедренных или коронарных артерий (или трансплантантов сосудов) в количестве, достаточном для трансфицирования клеток желаемого участка.
EA199600103A 1995-02-28 1996-02-27 Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре EA001616B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39620795A 1995-02-28 1995-02-28
US08/485,472 US5792453A (en) 1995-02-28 1995-06-07 Gene transfer-mediated angiogenesis therapy
PCT/US1996/002631 WO1996026742A1 (en) 1995-02-28 1996-02-27 Gene transfer-mediated angiogenesis therapy

Publications (2)

Publication Number Publication Date
EA199600103A1 true EA199600103A1 (ru) 1997-09-30
EA001616B1 EA001616B1 (ru) 2001-06-25

Family

ID=27015408

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199600103A EA001616B1 (ru) 1995-02-28 1996-02-27 Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре

Country Status (9)

Country Link
US (2) US6100242A (ru)
EP (1) EP0760682A4 (ru)
JP (2) JP3961019B2 (ru)
CN (2) CN1136920C (ru)
CA (1) CA2188575A1 (ru)
EA (1) EA001616B1 (ru)
HK (1) HK1008979A1 (ru)
IL (1) IL117309A0 (ru)
WO (1) WO1996026742A1 (ru)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US20020192198A1 (en) * 1998-04-21 2002-12-19 Elia James P. Method for growing human organs and suborgans
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6090618A (en) 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US7169764B1 (en) 1995-10-05 2007-01-30 Arch Development Corporation Promoter for smooth muscle cell expression
US5941868A (en) * 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
EP0888086B1 (en) 1996-02-15 2005-07-27 Biosense Webster, Inc. Excavation probe
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
ATE296117T1 (de) * 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
EP0969877B1 (en) * 1997-04-04 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
CN1260835A (zh) * 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
EA005157B1 (ru) * 1997-05-06 2004-12-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
WO1999001150A1 (en) * 1997-07-03 1999-01-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for treating, preventing and/or delaying ischemic cell death
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
ES2293473T3 (es) 1998-02-05 2008-03-16 Biosense Webster, Inc. Administracion intracardiaca de farmaco.
WO1999040197A2 (en) * 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
IL137765A0 (en) * 1998-02-11 2001-10-31 Univ California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU2006200170B2 (en) * 1998-02-11 2009-01-08 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
AU770384B2 (en) * 1998-05-30 2004-02-19 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
ATE348629T1 (de) * 1999-01-15 2007-01-15 Medstar Res Inst Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
US6440945B1 (en) 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
US6936594B1 (en) 1999-09-21 2005-08-30 Ryuichi Morishita Gene therapy for cerebrovascular disorders
US20040121942A1 (en) * 1999-11-02 2004-06-24 Kenneth Chien Method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
JP2003513942A (ja) * 1999-11-05 2003-04-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
US6748258B1 (en) * 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
WO2001048164A2 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
CA2412847A1 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
AU2002253785A1 (en) * 2000-11-08 2003-03-03 Boston Scientific Limited Catheter and implants for the delivery of therapeutic agents to tissues
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6962798B2 (en) * 2000-12-21 2005-11-08 Board Of Regents, The University Of Texas System Methods and compositions relating to a cardiac-specific nuclear regulatory factor
CA2433936A1 (en) * 2001-01-23 2002-08-22 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
WO2002089658A2 (en) * 2001-05-07 2002-11-14 New York University Microvascular free flaps for local or systemic delivery
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
SI1515752T1 (sl) 2002-06-19 2009-06-30 Univ Health Network Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20040127447A1 (en) * 2002-09-27 2004-07-01 Archer Stephen L. Augmentation of K+ channel expression using adenoviral vectors
US20040158289A1 (en) * 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
US7627373B2 (en) * 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
WO2004073484A2 (en) * 2003-02-24 2004-09-02 Yossi Gross Fully-implantable cardiac recovery system
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US20070237740A1 (en) * 2004-09-27 2007-10-11 Vical, Inc. Formulations and Methods for Treatment of Inflammatory Diseases
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
WO2007101106A2 (en) 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
ES2520044T3 (es) * 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
AU2009316380B2 (en) 2008-11-21 2016-02-04 The Children's Hospital Of Philadelphia Snake Factor V and methods of use as a procoagulant
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2022079082A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation
CN116406425A (zh) 2020-10-15 2023-07-07 豪夫迈·罗氏有限公司 用于va rna转录的核酸构建体
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5346812A (en) 1989-09-07 1994-09-13 The University Of Miami Teratogen assay
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5071962A (en) 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
US5586982A (en) * 1992-04-10 1996-12-24 Abela; George S. Cell transfection apparatus and method
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE69331526T2 (de) * 1992-11-18 2002-10-24 Arch Dev Corp Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
WO1995013392A1 (en) 1993-11-09 1995-05-18 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
DK0733103T3 (da) 1993-11-09 2004-07-12 Univ Johns Hopkins Fremstilling af höje titre af rekombinante AAV vektorer
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
JPH10511264A (ja) 1994-12-06 1998-11-04 ターゲティッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成のためのパッケージング細胞株
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
EA199900261A1 (ru) 1996-09-05 1999-10-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Генная терапия застойной сердечной недостаточности

Also Published As

Publication number Publication date
HK1008979A1 (en) 1999-05-21
JP3961019B2 (ja) 2007-08-15
JP2007161732A (ja) 2007-06-28
EP0760682A4 (en) 1998-09-09
JPH10501423A (ja) 1998-02-10
IL117309A0 (en) 1996-06-18
AU706050B2 (en) 1999-06-10
CN1541714A (zh) 2004-11-03
EP0760682A1 (en) 1997-03-12
WO1996026742A1 (en) 1996-09-06
CN100569297C (zh) 2009-12-16
US6100242A (en) 2000-08-08
CN1174509A (zh) 1998-02-25
US6174871B1 (en) 2001-01-16
CA2188575A1 (en) 1996-09-06
CN1136920C (zh) 2004-02-04
AU5028796A (en) 1996-09-18
EA001616B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
EA199600103A1 (ru) Способ лечения болезни сердца, фильтрованный инъекционный препарат аденовирусного вектора, способ получения вирусного штамма, рекомбинантный вектор, клетка-хозяин, способ получения рекомбинантного аденовирусного вектора, способ лечения болезни периферических сосудов и способ ограничения доставки трансгена и его экспрессии в одном органе или структуре
Beck Revascularization of the heart
CA2284720A1 (en) Methods and apparatus for transmyocardial direct coronary revascularization
BR9814491A (pt) Bioprótese de válvula cardìaca sem stent, e, processos para substituição total de raiz de uma válvula cardìaca aórtica endógena num paciente mamìfero, e para substituição cirúrgica de uma válvula cardìaca e um segmento de tecido vascular adjacente num paciente mamìfero
EA199900861A1 (ru) Усеченные белки, родственные фактору роста эндотелия сосудов
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
CA2303802A1 (en) Vascular prosthesis
DE69635968D1 (de) Therapeutischer Inhibitor von glatten Muskelzellen
DK0591385T3 (da) Sygdomsbehandling ved hjælp af site-specifik instillering af celler eller site-specifik transformation af celler og kits dertil
WO1995028907A3 (en) Megapoietin: a novel megakaryocyte growth promoting factor
Chiu et al. Selective arterialization of coronary veins for diffuse coronary occlusion: an experimental evaluation
AR004492A1 (es) Cabello artificial para implante y procedimiento para producir el mismo
EA200000828A1 (ru) Терапия ангиогенеза с помощью переноса генов и способы внутрисосудистой доставки генов
EA200200533A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo
WO2002013675A3 (en) Distally narrowed vascular grafts
MX9206335A (es) Composicion de difusion de tejido ex vivo para la difusion de tejidos y organos.
EA199901002A1 (ru) Методы и составы для лечения сердечной недостаточности и вентикулярной коррекции путем доставки in vivo ангиогенных трансгенов
WO2001035996A3 (en) Use of pdt to inhibit intimal hyperplasia
Duarte et al. Creating a free muscle flap by neovascularization: An experimental investigation
DE69332373T2 (de) Menschlicher epidermaler Gen-Promotor
Hammermeister et al. Coronary bypass surgery for stable angina and unstable angina pectoris
FR2485928B1 (fr) Organes artificiels pour assister la circulation sanguine, notamment pompes cardiaques et valvules
SU137839A1 (ru) Способ операции наложени меж артериального анастомоза больным с врожденными пороками сердца синего типа
Raper et al. Subacute pulmonary hypertension due to carcinomatous microembolism
Neelakandan Closed mitral valvotomy: Tactile control

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MK4A Patent expired

Designated state(s): AM BY KZ MD TJ RU